Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial.

摘要: OBJECTIVE To evaluate the effect of tamoxifen (TAM) combined with a somatostatin analogue, octretide (OCT) on advanced liver cancer and whether OCT is superior to regular chemotherapeutic agents 5-Fu mitomycin C (MMC). METHODS Thirty-nine patients inoperable were randomly subdivided into TAM+OCT group (n=24) (n=15). They received treatment for three months respectively. Blood cell count, function, immunologic blood alpha-FP was regularly measured. Liver lump extrahepatic metastasis examined by CT. The followed up after conducted survival analysis. RESULTS In group, complete response 4 patients, partial 7 no change 9 progressive disease patients; level ALT AST had noticeable change, IgE IgG increased (P<0.01), lowered (P<0.05). 11 patients. There conspicuous statistical difference in two groups. accumulative rates 6 months, 1 year 2 years 95.7% vs 41.2% 63.7% 21.1% 25.4% 0 Medium time 12.8 5.5 group. CONCLUSIONS excerts reliable therapeutic ER(+) hepatocellular cancer. It MMC increasing rate, prolonging time, reducing side-effects.